K1.1 mRNA / Sunshine Biopharma - LARVOL DELTA

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer (ACCESSWIRE) - "Sunshine Biopharma...announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for human hepatocellular carcinoma....Under repeated dosing, the full-length K1.1c was found to reduce growth of three different types of human HCC tumors in mice with good tolerability. Proof-of-concept study of the truncated version K1.1d was conducted to assess its anti-tumor activity in HCC models in mice. A preliminary study suggested the truncated form of K1.1c could be highly expressed in engrafted tumors and had significant anti-tumor activity in mouse HCC models in a dose-dependent manner."

Preclinical • Hepatocellular Cancer

Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma (ACCESSWIRE) - "When transfected into cultured human HCC cell lines and patient-derived HCC cells, K1.1 mRNA exhibited dose-dependent anti-proliferative activity in vitro. Following encapsulation in specifically engineered lipids, the resulting K1.1 mRNA-Lipid Nanoparticles (K1.1/LNP) were efficiently delivered to livers of mice in a dose-dependent manner in vivo. K1.1/LNP, under repeated systemic dosing, was found to reduce growth of two different types of human HCC tumors orthotopically grafted into the livers of immunodeficient mice. The pharmacodynamics of K1.1/LNP in intrahepatic tumors was well correlated with antitumor efficacy in mice."

Preclinical • Hepatocellular Cancer

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 (ACCESSWIRE) - "The Company's two proprietary drugs in development advanced to the animal testing stage for both SBFM-PL4 targeted for SARS Coronavirus infections and K1.1 mRNA for liver cancer. IND-enabling studies of Adva-27a anticancer compound were halted in November 2023 pending further analysis of unfavorable in vitro results obtained earlier in the year."

Discontinued • Preclinical • Hepatocellular Cancer

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project (GlobeNewswire) - "Sunshine Biopharma...announced that it has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle ('LNP') companies. The purpose of the collaboration is to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1. The Company’s collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1....The partner generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer."

Licensing / partnership • Preclinical • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor